The musculoskeletal system can be a target organ for adverse drug reactions (ADRs). Drug-induced muscle, bone or connective tissue injuries may be due to, i), primary direct drug action, or, ii), undirected consequence of generalized drug-induced disease. Musculoskeletal ADRs may be only temporarily disabling, such as muscle cramps, as well as in other cases may be serious and life-threatening, such as rhabdomyolysis. In the last few years there has been an increasing awareness of musculoskeletal ADRs. Some recent drug safety issues dealt with serious or uncommon musculoskeletal reactions like rhabdomyolysis associated to statins and tendon rupture associated to fluoroquinolones. In this review, we firstly selected those drug classes having a significantly high percentage of musculoskeletal disorder reports in the WHO adverse drug reaction database, maintained by the Uppsala Monitoring Centre. Secondly, the different musculoskeletal ADRs were closely analyzed through the data obtained from an Italian interregional ADRs spontaneous reporting database. The findings on drugs associated to different musculoskeletal disorders, have been integrated with a review of the epidemiological data available in the literature. For the most involved drugs (HMG-CoA reductase inhibitors, fluoroquinolones, corticosteroids, bisphosphonates, retinoids) the underlying musculoskeletal ADR mechanisms were also reviewed and discussed.
INTRODUCTION
The burden of adverse drug reactions (ADRs) on public health is high, as suggested by Lazarou et al. in a milestone meta-analysis, where ADRs were found to have caused over 100,000 deaths in the United States in 1994 [1] . According to a recent prospective study on two large general hospitals in England, ADRs continue to represent an important cause of morbidity and mortality, accounting for 1 out of 16 hospital admissions and being responsible for the death of 0.15% of total admitted patients. Most ADRs were predictable from the known profiles of drugs and therefore likely to be preventable [2] . A better knowledge of mechanisms of ADRs is therefore crucial for the early acknowledgment of drug toxicity-related symptoms in different systems and organs. The objective of this review is to focus on ADRs occurring as muscle and bone disorders which may be less promptly recognized as compared to skin or allergic reactions.
The musculoskeletal system can be a target organ for ADRs. Drug-induced muscle and bone injuries may be due to a primary direct drug action, or may be part of a more generalized drug-induced disease (e.g. drug-induced polyneuropathy). Musculoskeletal ADRs may be only temporarily disabling, such as muscle cramps, as well as may be a serious and life threatening conditions in other cases, such as rhabdomyolysis [3] . In the last few years there has been an increasing awareness of the adverse effects of drugs on musculoskeletal system. Some recent drug safety issues dealt *Address correspondence to this author at the Department of Medicine and Public Health, Section of Pharmacology, University of Verona, Policlinico G.B. Rossi, Piazzale L. Scuro 10, 37134 Verona, Italy; Tel: +39-045-8074245; Fax: +39-045-581111; E-mail: roberto.leone@univr.it with serious or uncommon musculoskeletal reactions like rhabdomyolysis associated to statins and tendon rupture associated to fluoroquinolones. In 2001 cerivastatin was withdrawn from the world market because of the potential risk for severe myotoxic effects. The causal association between HMG-CoA reductase inhibitors and rhabdomyolysis, is currently well known and described in literature [4, 5] . However the epidemiology of most musculoskeletal adverse reactions is documented mainly through case reports or spontaneous pharmacovigilance data and doctors and health professionals are often not trained to recognise the drugs as the possible cause. In a French hospital, a prospective analysis from biochemical laboratory data based on serum creatinine phosphokinase (CPK) values (over twofold normal), estimated a muscular ADRs incidence of 7.2 (95%CI, 2.6-15.7) per 10,000 inpatients and 9.3 (95%CI, 5.8-14.1) per 10,000 outpatients over a 12 week period [6] .
An updated knowledge on the most involved classes of drugs and of the mechanisms underlying musculoskeletal ADRs can be of great help for, i), diagnosis, ii), reduced damaging effects (potential reversibility), and, iii), prevention of negative outcome.
In this review, as a starting point for investigating musculoskeletal ADRs, we firstly selected those drug classes having a significantly high percentage of musculoskeletal disorder reports in the WHO adverse drug reaction database, maintained by the Uppsala Monitoring Centre. Secondly, the different musculoskeletal ADRs were closely analyzed through the data obtained from an Italian interregional ADRs spontaneous reporting database. The findings on drugs associated to different musculoskeletal disorders, have been integrated with a review of the epidemiological data available in the literature. For the most involved drugs (HMG-CoA reductase inhibitors, fluoroquinolones, corticosteroids, bisphosphonates, retinoids) the underlying musculoskeletal ADR mechanisms were also reviewed and discussed.
PHARMACOVIGILANCE DATA
The principal goal of pharmacovigilance is the detection of adverse events related to the use of drugs that are unknown or novel in terms of their clinical pattern, severity or frequency. Many countries worldwide developed systems to collect and analyse the spontaneous reports of ADRs from doctors, nurses, citizens. In this review, we firstly selected a "top list" of worldwide drugs associated with musculoskeletal reactions from the WHO database on spontaneous reporting, managed by Uppsala Monitoring Centre (the UMC), within the WHO Programme for International Drug Monitoring [7] . At present, this database contains 3,700,000 reports coming from 78 countries with 2.5% of musculoskeletal reactions from a total of more than 7,000,000 ADRs. Although in reference books the muscle, bone and connective tissue disorders are usually grouped in the same chapter, we limited our investigation on the first two system organs that, in the terminology used in spontaneous reporting databases, also include tendon disorders. Other drug-induced connective tissue disorders are beyond the scope of this review. Moreover, we excluded from this analysis the vaccine-related musculoskeletal complaints that often refer to a reaction in the site of injection or are part of a general reactivity like flu-like syndrome. Table 1 shows the drugs selected from this database according to two criteria, i), when associated with more than 1000 musculoskeletal ADRs, and, ii), when the musculoskeletal reactions represent a percentage higher than 3% compared to the total ADRs. For drugs reported in Table 1 , musculoskeletal complaints appear to be frequent. However, it should be pointed out that spontaneous reporting is influenced by several factors such as degree of under-reporting, consumption of drugs, notoriety and indication bias.
It is well known that lipid lowering agents (statins and fibrates) are implicated in muscle damage, and that fluoroquinolones can induce arthropathies and tendon disorders as well. It is also recognized that osteoporosis is a major problem for patients on continuous steroid treatment. The bone toxicity due to hypervitaminosis A is a very old problem and arthralgia, back pain, musculoskeletal aches and pain are frequently observed in patients receiving synthetic retinoids. On the other hand, the large number of muscle and bone complaints associated with bisphosphonates, teriparatide or raloxifene, could be influenced by an indication bias, since these drugs are used in osteoporosis and patients often suffer musculoskeletal pain. With novel and more potent bisphosphonates availability, the major concern for long-term therapy is the development of osteonecrosis of the jaw. Second generation cephalosporins, angiotensin-II receptor antagonists, and proton pump inhibitors are drugs largely used worldwide and with a high rate of ADRs reporting. Patients treated with antibiotic therapy often complain of mild muscle or bone troubles, not necessarily caused by the drugs. For proton pump inhibitors it is now under debate whether a possible causal link with myopathy exits, as reported below in this review. A further step in exploring musculoskeletal ADRs was the investigation, in an Italian context, of the different ADRs affecting bone, muscle, and cartilage. In order to closely examine musculoskeletal ADRs we analyzed the Italian Interregional Group of Pharmacovigilance (GIF) database, which collects ADR reports from five Italian Regions and is managed by our group [8] . The physicians and other health care providers are requested to send the observed suspected ADRs, defined as "any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product". To date, the GIF database contains 33,035 reports, vaccine ADRs excluded, representing for approximately 60% of total Italian reports during 2005. The algorithm used to assess causality is based on the WHO criteria [9] . Only the reports with a certain, probable or possible causality assessment are included for the analyses. In the GIF database, vaccines excluded, a total of 1604 reports (4.8%) involved the musculoskeletal system as the target organ, causally attributed to 331 different drugs. Among these reports, the causality assessment was certain in 5.8%, probable in 56.1% and possible in 38.1%. Fifty-eight percent of musculoskeletal ADRs involved adult patients, 39% elderly (> 65 years), and only 3% children or adolescent (< 18 years). The female/male reporting ratio was 1.2. These data are not significantly different from those for the other ADRs contained in the GIF database. Table 2 shows the principal musculoskeletal ADRs with more than 60 reports, and the associated drugs, in the GIF database. Myalgia is the most frequently reported reaction accounting for nearly 50% of total musculoskeletal ADRs.
Myalgia is clinically associated with muscle pain and weakness, it may be accompanied by an increase in the enzyme creatinine phosphokinase (CPK) in serum and is associated with several drugs, as a very common complaint and can be an early symptom of other drug-induced disorders such as neuropathy, myopathy or immunological diseases. In addition to myalgia, myopathy/rhabdomyolysis are reported for lipid lowering drugs, but also for antipsychotic drugs, corticosteroids, fluoroquinolones and macrolides. For drugassociated joint disorders, the GIF database includes mild symptoms like arthralgia and severe conditions such as arthritis or arthropathies. Besides statins and fluoroquinolones, whose damage to joints is known, other widely used drugs are suspected to be responsible for such complaints.
Although it has been known for some years that fluoroquinolones can cause tendon disorders, the association with statins and corticosteroids is however a more recent finding. The strong association between osteonecrosis of the jaw and bisphosphonates therapy has recently emerged and more than a hundred cases have been observed throughout the world. Based on these findings integrated with literature data, the drugs associated with musculoskeletal disorders will be dealt separately later on, starting from the ones with the highest evidence.
LIPID LOWERING DRUGS
The most common forms of statin adverse reactions are myalgia and myopathy. Statin-induced myalgia [10] is characterized by a muscular symptomatology not accompanied by changes in levels of CK, whereas during myopathy an elevated CK level is observed [11] [12] [13] [14] [15] . The former reaction is characterized at the bioptic level by mitochondrial dysfunction and increased lipid storage; the myopathy is accompanied by cell infiltration and inflammatory activity. The more severe ADR is rhabdomyolysis [4, 11, 12, [15] [16] [17] [18] with loss of cross-striations and nuclei, without cell infiltration. Significant myopathy has been estimated to occur in 0.1% to 0.5% of patients during clinical trials, with an increase during concomitant fibrate therapy [12] ; one epidemiologic study estimated the incidence of myopathy associated with statins at 2.3 per 10,000 person-years and suggested that fibrate use as a monotherapy conferred a 5.5-fold increased risk compared with when statins are used alone [13] . [4] . Progression of myalgia to rhabdomyolysis is fortunately rare, but if progressive muscle symptoms are ignored, fatalities can then occur. Therefore, clinicians need to be aware of these potential effects and to discuss signs and symptoms of muscle toxicity with their patients in order to improve the benefit-risk profile of these drugs. The most recent published evidence on lipid lowering drug-induced muskoloskeletal ADRs are summarized in Table 3 .
Statins have been shown to induce inhibition of protein synthesis and loss of differentiated rat myotubes in vitro. Several mechanisms are probably involved: supplementation studies showed that farnesol and geranylgeraniol, but not squalene, are able to prevent these effects induced by statins [19] . The potential mechanism may be therefore through blockade of farnesyl pyrophosphate and geranylgeranyl pyrophosphate production (enzymatic steps in the cholesterol synthetic pathway which is, not surprisingly, modified). These two enzymes, however, contribute to activate regulatory proteins, small GTP-binding proteins (e.g., Ras, Rac, Rho, etc.) which promote cell maintenance and growth, and attenuate apoptosis [20] . Therefore, statins may induce skeletal myocytes apoptosis through inhibition of their formation. Since reduction of cholesterol synthesis has been shown to be high in endothelium, toxicity at the level of muscle vasculature should be also taken in consideration. A decrease in muscle Coenzyme Q10 (CoQ10), a component of the mitochondrial respiratory chain, may have a role in the pathogenesis of statin-related myopathy [21] . CoQ10 supplementation ameliorate the symptoms of statin-associated myopathy, but there is no sufficient evidence to support its routine use for preventing the ADRs of statin therapy [22, 23] or to link statin therapy to pathologically decreased CoQ10 tissue level [24] . Statins may also modify the electrophysiological properties of muscle cell membrane. Decreased Na + /K + ATPase pump density, with an elevated sarcoplasmic Ca ++ and myofibre necrosis and apoptosis, has been shown to occur in skeletal muscle after lovastatin [25] . Simvastatin has been reported to reduce Cl -conductance, an effect that may limit after-hyperpolarization and facilitate hyperthermia [26] . These effects on cell permeability need to be investigated more as one of the possible mechanisms involved in statin-induced myopathy.
The inhibition of the glucuronidation pathway has also been investigated. Glucuronidation is a common metabolic pathway for statins biotransformation to lactones [27] . Interaction studies suggest that gemfibrozil interaction with statins occurs at the level of this pathway, according to preclinical studies showing an inhibition of simvastatin glucuronidation [28] .
Fibrates also induced skeletal muscle ADRs, but the mechanisms involved may be different. The interaction between fibrates (HMG CoA synthase depletion) and statins (HMG CoA reductase inhibition) may also have a downstream synergistic influence on mevalonate pathway at the level of isopentenyl pyrophosphate (IPP) synthesis for the production of selenoproteins. Sec-tRNA selenocysteine isopentylation governs the expression of all selenoproteins but it is functional (mature form) only after isopentylation of adenosine 37 [29] . tRNA isopentenyl transferase is the enzyme responsible for such maturation. IPP is a direct metabolite of mevalonate and substrate of tRNA isopentyltransferase. Statins block the formation of mevalonate as a downstream consequence of HMG CoA reductase inhibition, as well as fibrates do. In vitro, selenoproteins synthesis was shown to be reduced by lovastatin [30] . Since statins and se- 
FLUOROQUINOLONES
Fluoroquinolones are an important group of antibiotics widely used in the treatment of various infectious diseases in adults. Their use is currently contraindicated in children and adolescents because animal studies have shown lesions and destruction of cartilage in weight-bearing joints in immature animals. Although long-term effects on articular function and growth are generally unknown, many Authors presently recommend that contraindications in children should be reconsidered based on analysis between risk factors and benefits that quinolones offer in pediatrics [32, 33] . A review of three quinolones (ciprofloxacin, ofloxacin, and nalidixic acid) involving over 7,000 children, did not find negative effects on the linear growth of children, however follow-up data (ranging from 1 week to 12 years) are available only for about 500 patients [34] . Another study determined that ciprofloxacin for "life-saving" treatment in infants was safe; no osteoarticular problems or joint deformities were observed at 42 months following administration [35] . Similar evaluations were drawn from the absence of arthropathy during the 4-6 weeks of follow-up of a randomised controlled study in Bangladesh, where single-dose of ciprofloxacin was compared with 12-dose erythromycin for childhood cholera [36] . Data from spontaneous reporting suggest that general musculoskeletal-related ADRs occur more frequently in association with fluoroquinolones than other antimicrobial [37] . Arthralgia and myalgia are frequently reported by patients, but the most severe disorders include arthropathies and tendinopathies [38, 39] . In clinical studies, quinoloneassociated arthropathy has been reported to occur in about 1% of patients, causing pain, stiffness and swelling of involved joints, usually within the first few days of therapy. After quinolone discontinuation, arthropathy usually resolves within days to weeks [40] .
The arthropathogenic effects of quinolones have been described in juvenile animals of multiple species and several studies have been performed to clarify the underlying mechanism leading to cartilage damage, even if the mechanism of quinolone-induced arthropathy is still unknown [41, 42] . Quinolones have an inhibitory effect on DNA, collagen and proteoglycan synthesis and on the formation of oxygenderived reactive molecules [43, 44] . Chondrotoxicity is also explained by their chelating properties for bi-and tri-valent ions, causing formation of radicals in immature joint cartilage, and eventually irreversible lesions [41] . Recently, it was suggested that quinolone-induced arthropathy is possibly associated with the magnesium-chelating properties of these drugs leading to an altered functionality of integrin receptors on chondrocyte surface [45, 46] . The first cases of tendon disorders related to fluoroquinolones were described in men in 1983 [47] ; over the last few years the number of clinical reports on tendinopathies related to fluoroquinolones is increased [47] [48] [49] [50] [51] . A population based case-control study in United Kingdom indicated that 2-6% of Achilles tendon ruptures in people older than 60 age can be attributed to fluoroquinolones, with an Odds Ratio of 28.4 (95%CI, 7.0-115.3) for ofloxacin, 14.2 (95%CI, 1.6-128.6) for norfloxacin, and 3.6 (95%CI, 1.4-9.1) for ciprofloxacin [52] . The risk is the highest in elderly people concomitantly treated with corticosteroids, and symptoms frequently develop after the first 1-2 weeks of treatment, whereas tendon ruptures occur within 2-3 weeks [52] [53] [54] . Among fluoroquinolones, levofloxacin was associated with the highest tendinitis reporting rate [37] , an observation supported also by the WHO database in which levofloxacin ranked first for tendon ruptures [51] . In Table 4 , are reported the most recent data on fluoroquinolone-induced musculoskeletal ADRs.
In spite of the relatively large volume of case-based evidence, the pathophysiology of fluoroquinolone-induced tendinitis and tendon rupture is still unclear. Since there are similarities between tendons and cartilage, common mechanisms might exist for chondrotoxicity and tendontoxicity. As mentioned above, the imbalance of nutrients and electrolytes produced by quinolones and other chelating agents may alter the function of regulating proteins (e.g., integrins) of both chondrocytes and tenocytes. Furthermore, tendons can not easily compensate these altered functions because of their poor vascularization. Recent results on cultured human tendons provided evidence that apoptosis, a consequence of changes in beta-1 integrin receptors and Map-kinase pathway, has to be considered as a final event in the pathogenesis of fluoroquinolone-induced tendinopathies [55] . The findings that quinolone-induced damage on connective tissue is partially due to magnesium chelation also support the observation that patients with a latent magnesium deficiency could be at an increased risk of tendon disorders [56] .
CORTICOSTEROIDS
Corticosteroids play a major role in the treatment of asthma, inflammatory joint disorders and other inflammatory and autoimmune diseases affecting gastrointestinal tract and central nervous system. In spite of prescription and warning messages, they are often administered for long-term, as well as for short-term (e.g., high dosage regime during short-term [57] . The incidence of myopathy varies from 7 to 60% and can occur after shortterm high-dose steroid administration (e.g., in exacerbation of asthma) as well as after chronic treatment [58] [59] [60] [61] .
Corticosteroid-induced myopathy is correlated with increased CK level in type II fibres, with high glycolytic and low oxidative activities [60] . At a microscopic level, there are non specific histological changes, including variation of fibre size (type II fibre atrophy), centralization of nuclei, inflammation and occasional necrosis. At a biochemical level, the inhibition of protein synthesis in type II muscle fibres appears as the most detrimental event [62] . This correlates with lower levels of initiation factor eIF4E, which control mRNA binding to the 43S pre-initiation complex, and reduction of IGF-1 expression with a consequent decrease of its anti-apoptotic effects [63] . The net result is an enhancement of protein catabolism and muscle apoptosis [64] . Glutamine synthetase activity is also increased by both corticosteroidinduced protein synthesis inhibition, and by proteolysis [65] . Glutamine synthetase activity has a pathogenic significance (imbalance of energy production) which is counteracted by glutamine supplementation. Also note that glutamine synthetase activity in skeletal myocytes is under the control of IGF-1 factor, whose levels are lowered by corticosteroids [66] . Glycogen phosphorylase activity is significantly decreased by corticosteroid treatment. This effect, which is associated to muscular atrophy and weakness induced by increased levels of glycogen concentration, may be an additional mechanism of corticosteroid-associated myopathy.
Osteoporosis is one of the serious complications of oral corticosteroid treatment. Several studies report a decrease in bone mineral density irrespective of the disease being treated [67] [68] [69] [70] . A meta-analysis shows that oral corticosteroids treatment using more than 5 mg daily leads to a reduction in bone mineral density and a rapid increase in the risk of fracture [71] . Fracture risk has been associated both with oral and with inhaled corticosteroids [72, 73] . In Table 5 , are reported the most recent data on corticosteroid-induced musculoskeletal ADRs.
Bone loss is dose and time dependent even though there are discrepancies on the involvement of the different glucocorticoids. Long-term glucocorticoid treatment impairs intestinal calcium absorption, suppresses osteoblastic formation, and stimulates osteocyte apoptosis [74] . The possible mechanisms involved may be different, since the pathophysiology is complex and still unclear (Fig. 1) . One potential major mechanism is imbalance of calcium and phosphate metabolism. Calcium absorption is reduced in the intestine and renal excretion is increased [75, 76] . The effects are not mediated by changes in vitamin D metabolism or of levels of vitamin binding protein [77] . Indirectly, there may also be the involvement of parathyroid hormone (PTH), but available data are conflicting on the role of PTH as a mechanism of glucocorticoid ADRs [78] . Glucocorticoid receptors are expressed in osteoclasts [79] . Different in vitro effects have been reported on these cells depending on culture experimental conditions. Dexamethasone increases the proresorption ratio in marrow stromal cells, but data on bone resorption are still inconsistent [80] . Increased trabecular perforation by bone microarchitecture studies suggests a marked decrease in bone formation as a potential mechanism underlying glucocorticoids-induced osteoporosis. Modulation of synthesis of bone-specific proteins, including the early transcription factor cbfa-1 -involved in osteoblastic differentiation -has been reported [81] . The glucocorticoid ADRs effect on marrow mesenchymatous cells is complex. It certainly includes differentiation to adipocytes, an effect that probably involves an interaction between the nuclear glucocorticoids receptors and the PPAR 2 transcription factor, which is needed for adipocyte differentiation [82] . Other effects are decreased synthesis of type I collagen by mature osteoblasts, reduced expression of IGF-1 (an autocrine growth factor for osteoblasts) and of its binding proteins 3, 4 and 5 [83] , decreased osteoblasts adhesion to extracellular matrix [84] , promotion of matrix breakdown and stimulation of collagenase activity by inhibition of collagenase inhibitor TIMP-1 [85] (Fig. 1) . There is evidence that glucocorticoids may enhance the response of osteoblast to PTH by increasing the number of PTH receptors. A similar effect has been shown as an amplification of endothelin-1 vasoconstriction on osteoblasts [86] . Very recent data suggest an involvement of nitric oxide (NO) synthase in glucocorticoid-induced osteoporosis. The mechanistic link is still not elucidated, but studies in rats showed that NO improves osteoporosis induced by methylprednisolone [87] . This evidence suggests a potential role for the NO mechanisms but more data are needed.
BISPHOSPHONATES
Bisphosphonates (BPs) is an important class of drugs used to treat osteoporosis, Paget disease, multiple myeloma and metastatic cancer to the bones. BPs have a potent inhibitory effect on osteoclastic activity and induce apoptosis [88, 89] . The novel aminobisphosphonates, alendronate, pamidronate, risedronate, zoledronic acid, and ibandronate, have higher potency due to nitrogen in the side chain of the molecule. These drugs also have antiangiogenenic and antitumor effects [90, 91] . BPs are generally considered welltolerated drugs with minimal ADRs, even though long-term risks associated with prolonged BP exposure have not been fully described yet. One of the concerns is the very prolonged half-life of these compounds which are incorporated into the skeleton without being degraded; for example the estimated half-life for alendronate is up to 12 years [92] .
After BPs use in oncology, approved in 1995, and with novel more potent drugs available, the major concern for BPs long-term therapy is osteonecrosis of the jaw (ONJ). Clinically, ONJ appears as an area of exposed yellow-white hard bone with smooth or ragged borders, extraoral or intraoral sinus tracts may be present. The ONJ can develop spontaneously or more often after dental treatment. The disorder is usually painful, but sometime is asymptomatic [93] . The first bisphosphonates-associated ONJ cases were reported in 2003 [94] [95] [96] . After this alert, several papers appeared in the literature describing other cases of ONJ mainly in oncologic patients treated with IV BPs [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] . In particular, Durie and coll. [113] reported the results of a survey by the International Myeloma Foundation on 1203 patients, the estimated incidence of ONJ among the patients receiving zoledronic acid or pamidronate was 10% and 4% respectively. Noteworthy, the mean onset time of ONJ was 18 months among patients treated with zoledronic acid and 6 years among those treated with pamidronate. In an other study in the US [114] Recently, a systematic review [115] on bisphosphonates and ONJ summarized the main characteristics of this adverse drug reaction. The main damage site is the mandible (65% of reported cases), but also the maxilla (26%) or both (9%) are affected. Multifocal or bilateral involvement is slightly more common in the maxilla than in the mandible (31% vs. 23%). Females are affected more than males with a ratio of 3: 2. Interestingly, the disease appears more frequently among pa- tients who have received invasive dental treatment (60% of reported cases) or among those with other dental problems (e.g., periodontal pockets, untreated caries, wearing dentures), although spontaneous cases exist. The greater number of ONJ cases occurs in patients treated with IV BPs (zoledronic acid involved in 35% of reported cases, pamidronate 31%, and ibandronate 0.3%) generally for multiple myeloma or metastatic breast cancer. In 28% of reported cases patients were treated with two IV BPs, mainly zoledronic acid and pamidronate. Also oral bisphosphonates (alendronate and risedronate) for osteoporosis or Paget disease can rarely cause ONJ. Zoledronic acid has been approved in the US in 2001, therefore it seems to be more toxic than pamidronate, marketed 10 years before. Clodronate, a non-aminobisphosphonate, has not been implicated in the development of ONJ. The median duration of BP use before the onset of osteonecrosis range from 22 to 39 months. The concern is that with more patients taking bisphosphonates for longer periods of time, more cases of ONJ may develop even in patients treated with the last marketed ibandronate.
The mechanisms of bisphosphonate-associated ONJ have not been fully elucidated. Physiologically, bone microfracture and microcracks signal the need for new bone formation. This signal can be detected by osteoblasts which will initiate new bone mineralization. Since BPs strongly inhibit osteoclastic activity, no bone resorption takes place after the formation of microfractures. This process results in accumulation of the non-vital bone that is usually resorbed by osteoclasts. The jaws are covered only by thin mucosa and periosteum, so the bones are more exposed to microtrauma and infection, leading to osteonecrosis. However, some cases of avascular necrosis of the hip have been reported in patients treated with BPs, raising the possibility that bisphosphonates-associated osteonecrosis is a true systemic complication at the bone level [93, 115] .
No effective procedure to treat bisphosphonate-associated osteonecrosis is known, with surgical excision, prolonged antibiotic therapy and hyperbaric oxygen as the most used current interventions. Screening and prevention are needed to identify early lesions and improve prognosis. Before starting aminobisphosphonate therapy, in particular with IV administration in oncologic patients, it is strongly recommended to have a full dental assessment, to treat active oral infections, and to eliminate sites at high risk for infection. All patients should be instructed about the importance of maintaining good oral hygiene. Finally, a collaboration between oncologists and dentists is essential to reduce the risk of ONJ related to dental care [93, 114, 115] .
Besides ONJ, other musculoskeletal ADRs have been reported during BPs treatment. In one randomized controlled study, 11 out of 15 patients treated with pamidronate developed moderate to severe bone pain after the first dosing [116] . The pain may be due to an acute rise in the serum concentration of tumor necrosis factor [117] . Arthrosis and transient bone pain were observed in about 10% of patients treated with IV pamidronate for Paget disease [118, 119] . Similar findings were also observed for alendronate [120] . FDA received several reports of severe bone, joint, and muscle pain in patients treated with alendronate or risedronate [121] . Finally dose-related skeletal pain was observed in patients with Paget's disease treated with zoledronic acid intravenously [122] . The data suggest that arthralgia, myalgia and bone pain are possible class effects of bisphosphonates. In Table 6 , are reported the most recent data on bisphosphonate-induced musculoskeletal ADRs.
RETINOIDS
Retinoids are potent derivatives of retinol (the basic molecule of vitamin A), and have been proven to be important to improve the quality of life of many thousands of patients. However, a careful use of these important drugs is needed because of their side effects, many of which are similar to the clinical signs of the hypervitaminosis A syndrome. The bone toxicity due to hypervitaminosis A is a very old problem, as suggested by the 1.6 million-year-old skeleton discovered in 1973 in Kenya [123] . Musculoskeletal symptoms of vitamin A toxicity include muscle weakness, bone pain, bone abnormalities, hyperostosis, muscular stiffness and pain [124] . A double risk (OR, 2.1; 95%CI, 1.1-4.0) for hip fracture was observed in a Swedish epidemiological study, where in women a vitamin A intake greater than 1.5 mg/day was significantly associated to reduced bone mineral density [125] . Likewise, an increased risk of hip fracture was associated with long-term intake of high levels of vitamin A, from supplements and food, in a large prospective cohort study of postmenopausal women within the Nurses' Health Study [126] . These data are supported by results from the Rancho Bernardo Study [127] , where an inverse U-shaped association was found between vitamin A intake and bone mineral density. In this study the bone mineral density was optimal when vitamin A intake ranged from 0.6 to 0.9 mg/day, indicating that both low and high vitamin A intakes may compromise bone health. More recently Michaëlsson and coll. [128] provided further data on the bone toxicity of vitamin A from a population-based longitudinal cohort study. In this study, the risk of fracture in men was analysed in relation to the serum retinol levels. The relative risk was 1.64 (95%CI, 1.12-2.41) for any fracture and 2.47 (95%CI, 1.15-5.28) for hip fracture among men in the highest quintile for serum retinol (>2.64 mol/L), as compared to the middle quintile (2.17-2.36 mol/L). In contrast with these data a UK prospective nested case control study found no association between biochemical retinol status or supplement use and either hip fracture or any osteoporotic fracture. So, the Authors suggest that there is not sufficient evidence to support the elimination of retinol supplements from multivitamin supplements or restriction of intake of dietary preformed retinol or --carotene on the basis of skeletal risk [129] . On the other hand, a clinical review on vitamin A and osteoporosis conclude that, pending further investigation, supplements should not be used with the specific goal of improving bone health [130] .
The precise mechanism of bone toxicity of vitamin A is not sufficiently clear. Retinol is released in target cells and converted to retinoic acid, which exerts its effects by binding to specific nuclear receptors. These retinoic acid receptors have been identified in nearly every cell including osteoblasts, osteoclasts and chondrocytes. Retinoic acid suppresses osteoblast activity, stimulates osteoclast formation, and antagonizes the ability of vitamin D to maintain normal serum calcium levels. All of which may contribute to bone resorption and skeletal fractures [131] . Literature data regarding osteoporosis and demineralization due to the synthetic retinoid therapy are conflicting and not conclusive [132, 133] . Hyperostosic changes or calcification of tendons and ligaments, resembling those observed in diffuse idiopathic skeletal hyperostosis (DISH), are the most frequently reported skeletal ADRs associated with retinoids. DISH is common in the general population and increases with aging; patients receiving chronic retinoid therapy, particularly with higher doses, have a very high likelihood to develop DISHlike hyperostosis [133] . Monitoring skeletal toxicity during a single course of retinoid therapy is generally not indicated, while repeated short courses or long-term use of retinoids may require monitoring for skeletal toxicity [134] . In Table   7 , are reported the most recent data on retinol or retonoidinduced musculoskeletal ADRs.
Another relevant retinoid bone toxicity is the premature epiphyseal closure in children [133] . It has been suggested that this isotretinoin effect may be related to alterations in the characteristic pattern of chondrocyte gene expression [135] . Animal data indicate that activation of the retinoic acid receptors is necessary and sufficient to cause epiphyseal dysfunction or destruction [136] .
Arthralgia, back pain, musculoskeletal aches and pain are frequently observed in patients receiving isotretinoin [137] , however the discontinuation of therapy is only occasionally required. Myalgia occurs in up to 15% of treated patients with isotretinoin in some of the cases showing elevated creatinine phosphokinase levels [138] , more myalgia than expected is reported if patients perform physical activities [139] . Some cases of aseptic arthritis associated with isotretinoin therapy have been reported. A possible explanation of these cases involves the induction of lysosomal membrane solubilization and resultant cytopathic destruction of the synovia leading to increased sensitivity to mechanical injury [140] . Arthralgia, back pain and myalgia are also reported for acitretin [137] and alitretinoin [141] .
There are no data of musculoskeletal reactions for thirdgeneration retinoids (tazarotene, bexarotene) or for adapalene, apart from a few cases of myalgia with bexarotene, less frequent and severe with respect to other retinoids, observed during a clinical trial [142] . The third generation retinoids interact with fewer retinoid receptors than first-and second-generation, probably because they have less flexible structures. The relative lack of receptor specificity of earliergeneration retinoids may lead to greater side effects including musculoskeletal complaints [143] .
PROTON PUMP INHIBITORS
Omeprazole and other proton pump inhibitors (PPIs) are drugs used worldwide for treating oesophageal reflux and dyspepsia. PPIs have been shown to be well tolerated by patients, with a frequency of mild side effects of about 1-3% [144] . Headache, diarrhoea, skin rashes are the most frequently reported ADRs, while muscle cramps, myalgia, joint pain, and leg pain, developed in less than 1% of patients during treatment [145] . In the literature, anedoctal case reports suggested the association between PPI and severe muscular injury, often as a result of drug interactions [146] [147] [148] . A case of acute severe myopathy was recently observed after a single infusion of omeprazole, suggesting the need to moni- tor muscle injury markers when this treatment regime is used [149] .
The New Zealand Intensive Medicines Monitoring Programme found a possible positive correlation between polymyositis and omeprazole and in the WHO database there are 292 reports of myopathies with PPIs (excluding the high number of cases of myalgia) and in 15 patients the reaction re-occurred when the drug was reinstated, providing further evidence of a possible causal association between members of the PPI drug class and myopathy, including polymyositis [150] . However it should be pointed out that this evidence comes from spontaneous reporting systems which represents the best way for the early detection of warning and can support but not prove a causal association between a drug and an ADR. Following some case reports [151] of acute polyarthralgia in association with omeprazole, a nested casecontrol study did not confirm this signal [152] . In fact omeprazole use was not associated with an increased risk of inducing polyarthralgia compared with ranitidine and cimetidine.
Facing the very popular use of PPIs, the possible role of this class of drugs in the development of severe musculoskeletal ADRs should be considered, even if data from the literature suggest to take into account any possible confounding factor before attributing ADRs to PPIs.
ANTIPSYCHOTIC DRUGS
Neuroleptic malignant syndrome (NMS) is a rare but lifethreatening disorder usually induced by antipsychotic drugs, characterized by hyperthermia, extrapyramidal symptoms as rigidity, altered consciousness, autonomic dysfunction, including diaphoresis and incontinence and elevated serum creatinine phosphokinase levels. Prospective studies have reported NMS occurrence rates ranging from 0.07% to 2.2% of patients receiving neuroleptics [153, 154] . Recent literature data suggest that NMS due to novel antipsychotics, with lower affinity for the dopamine D2 receptor, exhibits less muscle rigidity than that seen with traditional antipsychotics [155] .
Severe muscle disorders as rhabdomyolysis -without evidence of NMS -has also been reported with typical and atypical antipsychotics such as haloperidol, clozapine and olanzapine [156] [157] [158] . Some cases of rhabdomyolysis were related to the correction of hyponatremia in patients developing psychogenic polydipsia, possibly complicated by newer antipsychotic drugs. The Authors recommended regular monitoring of muscle enzyme concentrations in antipsychotic-treated patients with concomitant hyponatremia secondary to psychogenic polydipsia, in order to detect rhabdomyolysis [159, 160] .
In a small study, decreased bone mineral density was observed in female, premenopausal schizophrenia patients receiving risperidone, but not in those receiving olanzapine. Age-adjusted bone speed of sound was significantly lower in women treated with risperidone as compared with patients treated with olanzapine when determined at radius and phalanx (p < 0.05), but not tibia. This effect is most likely due to persistent risperidone-induced hyperprolactinemia [161] .
ANTICOAGULANT DRUGS
The use of heparins results in a risk of osteoporosis complicated by bone fractures, with low-molecular weight heparins (LMWHs) carrying a lower risk than unfractioned heparin (UFH). This effect has been correlated with long term use (greater than 6 months) and doses exceeding 15,000 IU per day [162] . Osteoporosis has mostly been studied in pregnant women, where LMWHs appears to be safer than UFH, but they can still inhibit bone formation [163] . Calcium, vitamin D supplementation and weight-bearing exercise are recommended to obviate heparin associated osteoporosis [164] . It was suggested that osteoporosis may be due to heparininduced enhancement of collagenolysis or to enzyme inhibition [165] . By using animal models, it was demonstrated that heparin causes bone loss by increasing osteoclast number and activity, and by enhancing osteoclast formation, through MAP kinase pathway upregulation [166] .
Oral anticoagulants, such as warfarin, are vitamin K antagonists and exert an inhibition of the -carboxylation of glutamic acid residues, conversion that activates clotting factors as well as bone proteins [167] . On the basis of this mechanism and from growing bone observation in human and rat studies, the use of warfarin is considered a strong risk factor for osteoporosis. However, several observational studies aimed to answer the question of whether and how much warfarin exposure is associated with osteoporotic fracture in different patient populations, reached conflicting results [168] [169] [170] . In a very recent retrospective cohort study [171] in more than 14,000 patients with atrial fibrillation, long term use of warfarin was associated with a 25% increased risk of osteoporotic fractures, whereas -adrenergic antagonists may have a protective effect on bone density and risk of fracture. To minimize this risk, health care providers could give some advise when prescribing warfarin to elderly persons at high risk of falling, such as having adequate intake of calcium and vitamin D, regular exercise, to use walking aids and by discontinuing unnecessary drugs [172] .
MISCELLANEOUS DRUGS
Patients treated with anticancer, antiretroviral and immunosuppressive agents frequently complain of mild musculoskeletal symptoms such as myalgia and arthralgia, even through the generic characteristics of these reactions and the severity of patient conditions make it difficult to determine a causal relationship. In the literature there are reports of severe muscle reactions as rhabdomyolysis associated with specific anticancer drugs, but at the present there is no basis to formulate any sound hypothesis for a specific mechanism underlying muscle damage by these classes of drugs [173, 174] .
Regarding antiretroviral therapy, it is well known that zidovudine (ZVD) and other nucleoside-analogue reversetranscriptase inhibitors (NRTIs) are associated with skeletal and cardiac muscle pathologies, but there is no clear relationship between therapy duration, dose and severity of myopathies [175] . The precise nature of ZDV myopathies has not been well-defined yet, but in vitro studies have demonstrated that a possible mechanism is the impairment of skeletal muscle mitochondrial function [58, 176, 177] .
Cyclosporine therapy has been associated with myopathy, osteopathy, myalgia, muscle cramps and musculoskeletal pain. Interactions with statins due to common metabolism via the CYP3A4 pathway can result in significant increase of risk of rhabdomyolysis, as shown by several case reports [178] [179] [180] .
Musculoskeletal pain occurred in more than 10% of patients with chronic hepatitis treated with interferon alpha (INF alpha). Few cases of acute rhabdomyolysis associated with INF alpha in chronic hepatitis C, scleromixedema and melanoma have been reported. In most of them the manifestation of muscle injury occurred when the dose of INF alpha was being increased, suggesting that rhabdomyolysis represents at least a dose-dependent side effect of this drug [181] [182] [183] [184] . Myalgias and arthralgias have also been reported during interferon beta therapy, usually in conjunction with other flu-like symptoms. However, there is only one case of rhabdomyolysis associated to interferon beta 1a in a patient with multiple sclerosis [185] . Other cytokines which may induce musculoskeletal reactions are the granulocyte colonystimulating factor (G-CSF), e.g. lenograstim, pegfilgrastim, filgrastim. Transient bone and musculoskeletal pain are the most common ADRs of G-CSF, with an approximate 25-50% incidence; pain is usually mild or moderate in severity, not requiring therapy discontinuation, and can be controlled in most patients by acetaminophen [186] [187] [188] [189] [190] . Bone mineral loss, with features of osteopenia/osteoporosis, has been observed in patients treated with long-term G-CSF for severe congenital neutropenia. The relationship between bone mineral loss and G-CSF is not well clarified, but the findings of G-CSF-induced mobilization of osteoclastic progenitors in healthy volunteers support a possible role of these drugs in bone changes [191] .
A loss of bone mineral density, with trabecular bone being most affected, has been observed during chronic gonadotropin-releasing hormone (GnRH) treatment, related to the hypoestrogenic state [192] [193] [194] [195] . The effect has been observed in both sexes, but female patients have a lower initial bone mass than males, and their fracture risk is therefore higher. Osteoporosis is reversible in premenopausal patients after GnRH withdrawal [196] .
Osteoporosis and/or bone fracture associated with thyroid hormone (TH) therapy is controversial. TH has a direct effect on bone cells, by increasing both bone resorption and formation with adaptation of the systemic calciotrophic hormones. Increased bone turnover can result in mild osteoporosis [197] . Suppressive TH therapy was associated with significant bone loss in postmenopausal women, and replacement TH therapy was associated with bone loss in premenopausal women in a meta-analysis of controlled, cross-sectional studies [198] . The results of a study involving a large cohort of patients [199] indicate that the osteoporotic fracture rate of the femur was not significantly greater in patients under long-term levothyroxine therapy compared to control subjects (1.61% vs. 1.44%, respectively; p= 0.06). However, a significant difference in fracture rate was noted between male patients taking levothyroxine and control subjects (1.17% vs. 0.68%, respectively; p= 0.008). Since overt hyperthyroidism is well recognized to be associated with bone loss, it is possible that the reported reduction in bone density reflect an adverse event of previous thyrotoxicosis rather than therapy itself [197] . A decrease in bone mineral content has also been observed in some studies in hypothyroid patients treated with TH [200] [201] [202] [203] .
Anticonvulsants such as phenytoin and phenobarbital have been reported to cause alteration in bone metabolism with significant bone loss in persons receiving long-term therapy [204, 205] . Lamotrigine-associated rhabdomyolysis has been reported in hypersensitive patients during postmarketing surveillance [206] and a few case reports have noted myopathy, muscle pain and myositis with phenytoin therapy [207, 208] .
Rhabdomyolysis has been reported rarely in patients treated with antituberculous drugs (e.g. with isoniazid) [209] . Nongouty arthralgia is the most common adverse reaction observed during treatment with pyrazinamide, occurring in up to 40% of treated patients. This ADR is related to the inhibition of renal tubular uric acid secretion by pyrazinamide with elevation of serum uric acid concentrations [210, 211] .
Myopathy has been described in patients receiving amiodarone as both a single drug and in association with statins [212] [213] [214] [215] .
Arthropathy was reported in up to 39% of patients treated with deferiprone, an orally active iron-chelating agent used for the treatment of transfusional iron overload and in patients with thalassemia; these effects generally resolve with dosage reductions or drug withdrawal [216] . Arthropathy was reported in 13% of thalassemic patients (24 of 187) in a one-year multicenter safety study. Four of these patients interrupted therapy, but none discontinued deferiprone due to joint pain. Incidence of joint abnormalities increased as serum ferritin levels increased [217] . In a prospective study in patients with thalassemia major, with a treatment period of 4 years, joint symptoms decreased significantly after the first year of therapy [218] . Deferoxamine, another iron antagonist, has been found to cause bone dysplasia in children, due to possible mechanisms, such as defective function of irondependent enzymes and chelation of other minerals (e.g., zinc, copper, aluminium). Deferoxamine-induced bone dysplasia may cause decreased body height and spinal deformities [219] .
CONCLUSIONS
Muscle ADRs are represented by a heterogeneous group of manifestations, including mild and trivial symptoms as myalgia and severe life-threatening conditions as rhabdomyolysis. Likewise, ADRs affecting bone and joints range from general bone pain and arthralgia to life-conditioning pathologies as osteoporosis, or unexpected events as tendon rupture. Furthermore, the musculoskeletal disorders are not "typical" drug reactions like those occurring at the level of the skin and of the gastrointestinal tract. Therefore, it is often difficult to attribute a causal relationship to a drug therapy. It should be also taken in account the existing risk factors for musculoskeletal ADRs, for example elderly age, high dosage, renal disease, drug interactions, female gender for statins and long-term treatment for glucocorticoids [18, 69] .
Since the withdrawal of the HMG-CoA reductase inhibitor cerivastatin for the high risk of rhabdomyolysis in August 2001, the awareness of the possible causal role of drugs in inducing muscle-related ADRs increased. The association between fluoroquinolones and tendon rupture and the very recent observation of the link between bisphosphonates and ONJ have further contributed to draw the attention of health care providers toward the possible damage induced by drug therapy to the musculoskeletal system. In most cases, the incidence of this type of drug toxicity is not however documented by epidemiological studies and the mechanisms are not completely understood.
In such a context, spontaneous reporting can be a valuable source of data, keeping in mind its advantages and limits such as under-reporting and reporting biases due to selective ADR reporting. This review was based on the use of two spontaneous reporting databases: the WHO database which contains many reports, but is not homogeneous at least with respect to the source of information or the likelihood that the pharmaceutical product caused the adverse reaction, and the GIF database, which is smaller but contains high quality reports (more than 90% of reports are coming from physicians). Combining these two sources, together with an accurate overview of the literature and of case reports, we now provide an updated description of the principal classes of drugs causing musculoskeletal adverse reactions and of their underlying mechanisms.
A final consideration is toward the role of physical exercise in modern society and the consequence of it on ADRs. The health systems of several western countries have promoted programmes and facilities to increase physical activity levels in their sedentary population. On one side, this is expected to improve health, to prevent diseases and to decrease the use of drugs. On the other side, a growing mass of evidences indicate that physical activity and exercise training significantly interfere with the pharmacokinetics of several drugs [220] . Some of these pharmacokinetic changes may be predicted as consequence of exercise-induced changes in the blood flow and functionality of relevant organs including muscle, kidney and liver [221] [222] [223] or of training-induced modification of the volume and the composition of the body [224] . However, in most cases the changes in rates of absorption, distribution, excretion and metabolism of drugs occur unpredictably [225] [226] [227] . More studies need to be completed in this area before definite conclusions are made and clinical relevance can be established. Clinicians should be aware that the potential for interactions between drug use and physical activity exists, especially for drugs with a narrow therapeutic range and in patients who participate in extreme sporting activities. In addition, physical activity can simulate an ADR, for example in strenuous exercise CPK values are often elevated, in some cases to very high levels, [228, 229] which may confound whether the CPK elevation is due to the eventually administered drug, to exercise or a combination of both.
In conclusion, exercise-induced changes in drug pharmacokinetic and metabolism may modify the ADR profile of several drugs. Therefore, special attention should be given in the future by the surveillance agencies to possible links between ADRs and physical activity.
